Drugs for cancer chemotherapy generally have severe side effects, therefore, drug delivery systems that enable delivery of such drugs solely to tumor tissues are awaited. Liposomes are thought to be an ideal drug carrier, since they can encapsulate both hydrophilic and hydrophobic materials, and are biodegradable and essentially non-toxic. Liposomal encapsulation of drugs has been shown to enhance drug efficacy and to reduce side effects. Liposomes are especially suitable for delivery of anti-cancer agents, since liposomes have a tendency to passively accumulate in tumor tissues due to the leaky nature of the vascular endothelium of these tissues. [1] [2] [3] For this purpose, many anti-cancer agents or their derivatives such as doxorubicin, 4,5) daunorubicin, 6,7) vincristine, 8, 9) paclitaxel, 10,11) annamycin, 12) cisplatin, 13) camptothecin, 14, 15) and 5-fluorouracil, 16) have been encapsulated in liposomes to reduce side effects and enhance therapeutic efficacy. Furthermore, anthracyclines and some other agents can be encapsulated with about hundred percent trapping efficiency in preformed liposomes by remote-loading method. 17) This makes these anti-cancer agents quite favorable for liposomal formulation.
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A potent new anti-tumor podophyllotoxin derivative (4baminoalkyl-4Ј-O-demethyl-4-desoxypodophyllotoxin; TOP-53) has been developed that inhibits DNA topoisomerase II (topo II). 18) This compound showed about twice as strong inhibitory activity against topo II compared with VP-16, another podophyllotoxin derivative being clinically used in cancer chemotherapy. 18) VP-16 is known to exhibit a marked response against small cell lung cancer (SCLC), but a weak response against non-small cell lung cancer (NSCLC). This difference is believed to be caused by a lower topo II level and activity in NSCLC than that in SCLC. Therefore, TOP-53 having potent inhibitory activity is expected to at least be useful for SCLC treatment and possibly even to impact NSCLC. In fact, TOP-53 induced growth inhibition of human NSCLCs in a murine experimental model as well as various other murine solid tumors such as Lewis lung carcinoma, B16BL6 melanoma, colon26 NL-17 carcinoma, and so on. 18) Furthermore, these inhibitory effects were superior to those of VP-16. In this study, we liposomalized TOP-53 to determine whether or not the liposomalization enhanced the therapeutic efficacy and/or reduced the side effects of the agent.
MATERIALS AND METHODS
Materials TOP-53 was synthesized by Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan) as described previously. 18) Dipalmitoylphosphatidylcholine (DPPC) was the kind gift of Nippon Fine Chemical Co., Ltd. (Takasago, Hyogo, Japan). Cholesterol and calcein were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.), and n-octyl-b-D-glucoside was from Dojindo Co. (Kamimashiki, Kumamoto, Japan).
Preparation of Liposome Liposome was prepared as described previously. 4) In brief, DPPC and cholesterol (2 : 1 as a molar ratio) dissolved in chloroform were dried under reduced pressure and stored in vacuo for at least 1 h. Liposome was produced by hydration of the thin lipid film with 1 ml of 0.3 M sodium citrate (pH 4.0) and frozen and thawed for three cycles using liquid nitrogen. Then the liposome was sized by extrusion thrice through a polycarbonate membrane filter with a pore size of 100-nm. The pH outside of the liposome was adjusted to 7.5 by the addition of 0.4 ml of 0.5 M sodium carbonate and the suspension was diluted with 0.6 ml of 20 mM HEPES-buffered saline (pH 7.5). TOP-53-loading was performed by incubation of the liposomal solution with 1 ml of 5 mg/ml TOP-53 for 1 h at 60°C. The liposomal solution was centrifuged at 90000ϫg for 10 min (Hitachi, CS120EX) to remove the untrapped TOP-53. Then the liposome was resuspended in 1 ml of phosphate-buffered saline, pH 7.4 (PBS). To determine TOP-53-encapsulation efficiency, an aliquot of the liposomal solution was corrected be-To enhance the therapeutic efficacy as well as to reduce the side effect, we attempted to liposomalize 4b baminoalkyl-4-O-demethyl-4-desoxypodophyllotoxin (TOP-53), a novel and effective topoisomerase II inhibitor. More than 90% of TOP-53 was efficiently incorporated into the liposomes composed of dipalmitoylphosphatidylcholine and cholesterol by remote-loading method. Anti-tumor activity of liposomal TOP-53 against solid tumor was examined in vivo using colon26 NL-17 carcinoma model mice. Three doses of liposomal TOP-53 (12 mg/kg/dose) showed significant tumor growth suppression (97.5% reduction determined at day 25) and the increase in life span (33%) of tumor-bearing mice. Furthermore, one mouse out of 5 was completely cured after treatment. Since similar efficacy was observed in the free TOP-53 treated group, liposomalization does not contribute much to the enhancement of therapeutic efficacy. However, a slight but measurable damage at the injection site was observed when free TOP-53 was injected, and the damage was diminished by the liposomalization. Taken together, liposomalization reduces the side effect rather than enhancing the therapeutic efficacy when TOP-53 is used.
fore and after centrifugation, and was solubilized by the addition of n-octyl-b-D-glucoside for determination of the fluorescence intensity (Ex; 587 nm, Em; 642 nm). Liposomal solution was used for the following experiments after dilution with PBS to obtain adequate concentration of TOP-53.
Tumor Implantation and Therapeutic Experiment Colon26 NL-17 carcinoma cells were cultured in RPMI 1640 medium (Nissui, Tokyo, Japan) containing 10% fetal bovine serum (FBS, Sigma Chemical Co.) at 37°C in a CO 2 incubator. The cells were diluted with the same medium to obtain 5.0ϫ10 6 cells/ml suspension. Then 0.2 ml of the suspension was carefully injected intravenously into the tail vein of fiveweek-old Balb/c male mice (Japan SLC Inc. Shizuoka, Japan).
Liposomal or free TOP-53 (12 mg/kg/d), or PBS was injected intravenously into tumor-bearing mice at day 9, 14, and 19 after tumor implantation. Weight of each mouse, an indicator of side effect, and the size of the tumor were monitored daily thereafter. Two bisecting diameters of each tumor were measured with slide calipers to determine the tumor volume and calculation was performed using the formula 0.4 (aϫb 2 ), where "a" is the largest and "b" the smallest diameter. Tumor volume thus calculated correlated well with actual tumor weight (rϭ0.980). 4) The animals were cared for according to the animal facility guidelines of the University of Shizuoka.
Histopathological Analysis Colon26 NL-17 carcinomabearing mice were injected with three doses of liposomal TOP-53 (12 mg/kg/d as TOP-53), free TOP-53 (12 mg/kg/d) or PBS as described above. The mice were sacrificed under ether anesthesia at day 21. The tails were dissected out and fixed with 20% buffered formalin. After the tails were fixed again with 10% buffered formalin, tissue samples of 4 parts per tail were embedded in paraffin and thin sections were prepared, HE staining was then carried out. Histopathological changes were graded in 4 levels: Ϫ, normal; ϩ, slightly changed; ϩϩ, moderately changed; ϩϩϩ, greatly changed.
Statistical Analysis Variance in a group was evaluated by the F-test, and differences in mean tumor volume were evaluated by Student's t-test.
RESULTS

Antitumor Effect of Liposomal TOP-53
Before the in vivo experiment, trapping efficiency of TOP-53 into liposome and stability were examined. More than 93% of TOP-53 was encapsulated and did not leak out from the liposome during at least a week at 4°C (data not shown). The agglutinability of the liposomes in the presence or absence of 50% serum was monitored photometrically, and no obvious turbidity change was observed (data not shown).
Anti-tumor activity of liposomal TOP-53 was examined in Colon26 NL-17 carcinoma-bearing mice. This cell line was used in a previous experiment to evaluate the effectiveness of free TOP-53. 18) The previous study demonstrated that free TOP-53 suppressed the growth of s.c. implanted Colon26 and of spontaneous and experimental metastases of Colon26 sublines, NL-17 and NL-22, and that these anti-tumor activities were superior to those of VP-16. In this study, liposomal TOP-53 (12 mg/kg/d as TOP-53), free TOP-53 (12 mg/kg/d), or PBS as a control was injected intravenously into mice bearing Colon26 NL-17 carcinoma to evaluate the antitumor activity and side effects. As shown in Fig. 1a , liposomal TOP-53 potently suppressed tumor growth (97.5% reduction determined at day 25, significantly different from the control, pϽ0.001). Free TOP-53 also suppressed tumor growth to a similar extent (96.6% reduction determined at day 25, significantly different from the control, pϽ0.001). The mean survival time of control, free TOP53-treated, and liposomal TOP-53-treated groups was 57.8 d, 80.5 d, and 76.7 d, respectively: The increase in lifetime was 39% for TOP53-treated and 32% for liposomal TOP-53-treated groups, respectively. Furthermore, one mouse out of 5 was completely cured after treatment in both groups. These data indicate that free TOP53 and liposomal TOP-53 have quite similar anti-tumor activity. We also tested anti-tumor activity of free TOP53 and liposomal TOP-53 at 3 doses of 7 mg/kg and observed that the efficacy of the latter was not much different from that of the former (data not shown): Treatment of both free TOP-53 and liposomal TOP-53 at these doses also markedly suppressed tumor growth. Figure 1b shows the body weight change of these animals as an indicator of the side effects. Both free TOP-53-treatment and liposomal TOP-53-treatment induced a slite but measurable reduction in body weight loss. However, the reduction in weight was less and more transient for the liposomal TOP-53 treated group than for the free TOP-53 treated group, suggesting that the side effect of TOP-53 was diminished by liposomalization.
Histopathological Analysis of the Injection Site of TOP-53 During the therapeutic experiment, we observed the swelling of the tail of mice near the injection site of TOP-53. The swelling was observed in all free TOP-53-treated mice (nϭ5), however, liposomal TOP-53 did not induce such 784 Vol. 25, No. 6 Five-week-old Balb/c male mice (five per group) were implanted subcutaneously with Colon26 NL-17 carcinoma cells into their left posterior flank. At days 9, 14, and 19 after tumor implantation, they were injected intravenously with PBS (᭺), free TOP-a marked change at the injection site (data not shown). These observations were seen in all therapeutic experiments. Therefore, the tail was histopathologically analyzed after 3 doses of TOP-53 treatments. Treatment of free TOP-53 induced crust formation, acanthosis, dilatation of vessels, and ulcer neighboring the injection site ( Fig. 2, Table 1 ), while liposomalization of TOP-53 reduced these topical side effects. In fact, liposomal TOP-53 did not induce any tail damage considered 'greatly changed'.
DISCUSSION
In this study, we liposomalized TOP-53, a potent novel anti-tumor podophyllotoxin derivative that inhibits DNA topo II, 18) and investigated its anti-tumor activity against Colon26 NL-17 carcinoma. TOP-53 was readily encapsulated into liposome by the remote-loading method, suggesting that TOP-53 would be suitable for liposomalization. Liposomal formulation of anti-cancer agents is expected to enhance their growth inhibitory activity and reduce the side effects. For this purpose, we also previously liposomalized the anti-cancer agents adriamycin and vincristin. 4, 19) Adriamycin encapsulated in liposome showed enhanced therapeutic efficacy for reducing tumor growth and for prolonging the survival time of mice bearing Meth A sarcoma compared with free adriamycin. Moreover, adriamycin encapsulated in liposome reduced side effects compared with free adriamycin. 4) Here, we compared the therapeutic efficacy of free TOP-53 with that of liposomal TOP-53. Administration of liposomal TOP-53 caused marked suppression of tumor growth and an increase in the survival time of tumor-bearing mice, although enhanced efficacy by liposomalization was not observed. We did not use the long-circulating liposome in this study, and therefore, it is possible that passive accumulation of the drugs at the tumor site is not well achieved.
Even though the enhancement of therapeutic efficacy was not observed by the liposomalization of TOP-53, liposomal TOP-53 obviously reduced body weight loss, one of criterion of the side effect. Furthermore, topical side effects at the injection site were also reduced. Since TOP-53 itself is quite efficient in suppressing tumor growth, the reduction of side effects is beneficial for practical usage of the drug in cancer treatment.
